# Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects

> **NCT05719961** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** INS062 injection
- **DRUG:** Insulin Aspart
- **DRUG:** HR20014 injection
- **DRUG:** Insulin Aspart 30 Injection

## Key facts

- **NCT ID:** NCT05719961
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-05
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-07-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05719961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05719961, "Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05719961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*